191
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

, , , , , , , , , , & show all
Pages 1332-1336 | Received 22 May 2013, Accepted 23 Aug 2013, Published online: 01 Nov 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mark H. Kirschbaum, Paul Frankel, Timothy W. Synold, Zhiliang Xie, Yun Yen, Leslie Popplewell, Robert Chen, Omar Aljitawi, Joseph M. Tuscano, Kenneth K. Chan & Edward M. Newman. (2016) A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leukemia & Lymphoma 57:10, pages 2307-2314.
Read now

Articles from other publishers (5)

Prithi Raguraman, Akilandeswari Ashwini Balachandran, Suxiang Chen, Sarah D. Diermeier & Rakesh N. Veedu. (2021) Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation. Cancers 13:21, pages 5555.
Crossref
Yaqiong Zhan, Lushun Jiang, Xuehang Jin, Shuaibing Ying, Zhe Wu, Li Wang, Wei Yu, Jiepeng Tong, Li Zhang, Yan Lou & Yunqing Qiu. (2021) Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomedicine & Pharmacotherapy 133, pages 110996.
Crossref
Thomas Briot, Emilie Roger, Sylvain Thépot & Frederic Lagarce. (2018) Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today 23:12, pages 1936-1949.
Crossref
Abdullah Al Hasan & A.T.M. Zafrul Azam. 2018. Design of Nanostructures for Theranostics Applications. Design of Nanostructures for Theranostics Applications 341 436 .
Pedro Barata, Anil K. Sood & David S. Hong. (2016) RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treatment Reviews 50, pages 35-47.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.